Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

54,818 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade.
Zhou J, Mahoney KM, Giobbie-Hurder A, Zhao F, Lee S, Liao X, Rodig S, Li J, Wu X, Butterfield LH, Piesche M, Manos MP, Eastman LM, Dranoff G, Freeman GJ, Hodi FS. Zhou J, et al. Among authors: wu x. Cancer Immunol Res. 2017 Jun;5(6):480-492. doi: 10.1158/2326-6066.CIR-16-0329. Epub 2017 May 18. Cancer Immunol Res. 2017. PMID: 28522460 Free PMC article. Clinical Trial.
Bevacizumab plus ipilimumab in patients with metastatic melanoma.
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, Mihm MC Jr, Russell S, DiPiro PJ, Yap JT, Ramaiya N, Van den Abbeele AD, Gargano M, McDermott D. Hodi FS, et al. Among authors: wu x. Cancer Immunol Res. 2014 Jul;2(7):632-42. doi: 10.1158/2326-6066.CIR-14-0053. Epub 2014 Apr 21. Cancer Immunol Res. 2014. PMID: 24838938 Free PMC article. Clinical Trial.
Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X, Giobbie-Hurder A, Liao X, Connelly C, Connolly EM, Li J, Manos MP, Lawrence D, McDermott D, Severgnini M, Zhou J, Gjini E, Lako A, Lipschitz M, Pak CJ, Abdelrahman S, Rodig S, Hodi FS. Wu X, et al. Cancer Immunol Res. 2017 Jan;5(1):17-28. doi: 10.1158/2326-6066.CIR-16-0206. Epub 2016 Dec 21. Cancer Immunol Res. 2017. PMID: 28003187 Free PMC article.
Combined Anti-VEGF and Anti-CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes.
Wu X, Li J, Connolly EM, Liao X, Ouyang J, Giobbie-Hurder A, Lawrence D, McDermott D, Murphy G, Zhou J, Piesche M, Dranoff G, Rodig S, Shipp M, Hodi FS. Wu X, et al. Cancer Immunol Res. 2017 Jun;5(6):446-454. doi: 10.1158/2326-6066.CIR-16-0385. Epub 2017 May 4. Cancer Immunol Res. 2017. PMID: 28473314 Free PMC article. Clinical Trial.
54,818 results
You have reached the last available page of results. Please see the User Guide for more information.